SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Down – Time to Sell?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) gapped down before the market opened on Friday . The stock had previously closed at $15.21, but opened at $14.77. SELLAS Life Sciences Group shares last traded at $14.38, with a volume of 1,176,568 shares.

Analyst Ratings Changes

A number of brokerages recently weighed in on SLS. Alliance Global Partners restated a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, SELLAS Life Sciences Group presently has an average rating of “Hold” and an average target price of $10.00.

SELLAS Life Sciences Group Stock Performance

The stock has a market capitalization of $2.78 billion, a P/E ratio of -65.52 and a beta of 2.48. The stock’s fifty day simple moving average is $12.37 and its two-hundred day simple moving average is $8.05.

SELLAS Life Sciences Group (NASDAQ:SLS) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01).

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in SELLAS Life Sciences Group during the 2nd quarter worth about $257,000. California State Teachers Retirement System grew its position in shares of SELLAS Life Sciences Group by 31,891.4% in the 2nd quarter. California State Teachers Retirement System now owns 2,987,040 shares of the company’s stock valued at $44,089,000 after buying an additional 2,977,703 shares during the last quarter. Nykredit A S acquired a new stake in shares of SELLAS Life Sciences Group in the second quarter valued at about $27,000. Wellington Management Group LLP increased its stake in shares of SELLAS Life Sciences Group by 73.2% in the second quarter. Wellington Management Group LLP now owns 597,309 shares of the company’s stock valued at $8,816,000 after buying an additional 252,531 shares during the period. Finally, Bank of New York Mellon Corp bought a new position in shares of SELLAS Life Sciences Group during the second quarter worth about $7,823,000. 17.38% of the stock is owned by institutional investors.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.